182
Participants
Start Date
May 11, 2023
Primary Completion Date
December 31, 2025
Study Completion Date
December 31, 2025
GS-4528
Administered intravenously
Zimberelimab
Administered intravenously.
Chang Gung Memorial Hospital Linkuo Branch of the Chang Gung Medical Foundation, Taoyuan District
START MADRID_Hospital Universitario Fundacion Jimenez Diaz - Unidad de Ensayos Fases I, Madrid
START MADRID_HM Sanchinarro-CIOCC-Unidad de Ensayos Fases I, Madrid
Clinica Universidad de Navarra- Unidad Central de Ensayos Clinicos, Pamplona
Taichung Veterans General Hospital, Taichung
The University of Washington/FHCC, Seattle
National Taiwan University Hospital, Taipei
The Ottawa Hospital, Ottawa
University Health Network, Princess Margaret Cancer Centre, Toronto
Asan Medical Center, Seoul
Severance Hospital, Yonsei University Health Systems, Seoul
Samsung Medical Center, Seoul
NEXT Oncology-Hospital Quironsalud Barcelona - Unidad de Ensayos Fase 1, Barcelona
Hospital Universitari Vall D'Hebron- Oncology Service, Barcelona
St Bartholomew's Hospital, London
The Royal Marsden NHS Foundation Trust, Sutton
Lead Sponsor
Gilead Sciences
INDUSTRY